非小细胞肺癌程序性死亡配体-1表达与临床病理特征和常见驱动基因变异的相关性研究

doi:10.11904/j.issn.1002-3070.2023.02.005

实用肿瘤学杂志 ›› 2023, Vol. 37 ›› Issue (2): 117-122.doi: 10.11904/j.issn.1002-3070.2023.02.005

非小细胞肺癌程序性死亡配体-1表达与临床病理特征和常见驱动基因变异的相关性研究

龙朝恋, 李琨, 刘子臣, 张娜娜, 车南颖

北京市结核病胸部肿瘤研究所;首都医科大学附属北京胸科医院病理科,耐药结核病研究北京市重点实验室(北京 101149)

收稿日期:2022-10-21 修回日期:2023-02-01 出版日期:2023-04-28 发布日期:2023-05-30
通讯作者: 车南颖,E-mail:cheny0448@163.com
作者简介:龙朝恋,女,(1997-),硕士研究生,从事肿瘤免疫学方面的研究。
基金资助:
北京市属医院科研培育计划(编号:PX2022065)

The correlation between the expression of programmed death ligand 1 in non-small cell lung cancer and clinical pathological features and common driver gene mutation

LONG Chaolian, LI Kun, LIU Zichen, ZHANG Nana, CHE Nanying

Department of Pathology,Beijing Institute of Tuberculosis and Chest Tumors,Beijing Chest Hospital Affiliated to Capital Medical University,Beijing Key Laboratory of Drug-resistant Tuberculosis Research,Beijing 101149,China

Received:2022-10-21 Revised:2023-02-01 Online:2023-04-28 Published:2023-05-30

摘要/Abstract

摘要： 目的分析非小细胞肺癌(NSCLC)患者程序性死亡配体-1(PD-L1)表达与临床病理特征和常见驱动基因变异的相关性,为NSCLC患者免疫治疗提供理论依据。方法回顾性纳入首都医科大学附属北京胸科医院病理科2018年1月—2021年12月进行PD-L1免疫组织化学染色及EGFR、KRAS、ALK、ROS1、BRAF、RET、MET和HER2基因检测的NSCLC患者,分析不同病理特征与不同驱动基因变异对NSCLC患者PD-L1蛋白表达的影响。结果 PD-L1蛋白表达检测2 386例,阳性率为45.8%(1 093/2 386),其中低表达组(1%≤TPS≤49%)为62.0%(678/1 093),高表达组(TPS≥50%)为38.0%(415/1 093),不同临床病理特征PD-L1表达存在差异。多因素logistic回归分析显示吸烟史、淋巴结转移、病理亚型、EGFR突变、KRAS突变、ALK和MET突变是NSCLC患者PD-L1是否表达的独立危险因素(P＜0.05),淋巴结转移和EGFR突变是NSCLC患者PD-L1表达水平的独立危险因素(P＜0.05)。结论 PD-L1蛋白在吸烟、鳞癌、KRAS突变型、ALK阳性和MET突变型患者中阳性率高,在淋巴结转移和EGFR野生型患者中高表达。区别于EGFR阳性的NSCLC患者,KRAS、MET阳性的NSCLC患者有望从免疫检查点抑制剂治疗中获益。

关键词: 非小细胞肺癌, 驱动基因, 程序性死亡配体-1, 免疫检查点抑制剂

Abstract: Objective The aim of this study was to analyze the correlation between the expression of programmed death ligand 1(PD-L1)and clinical pathological features and common driver gene mutation in patients with non-small cell lung cancer(NSCLC),so as to provide theoretical basis for immunotherapy of NSCLC patients. Methods Retrospective inclusion of NSCLC patients who underwent PD-L1 immunohistochemistry staining and epidermal growth factor receptor(EGFR),Kirsten rat sarcoma viral oncogene(KRAS),anaplastic lymphoma kinase(ALK),RET proto-oncogene(RET),v-Raf murine sarcoma viral oncogene homolog(BRAF),ROS proto-oncogene 1(ROS1),human epidermal growth factor receptor-2(HER2),cellular-mesenchymal to epithelial transition factor(MET)gene testing from the Pathology Department of Beijing Thoracic Hospital Affiliated to Capital Medical University from January 2018 to December 2021.Analysis of the impact of different pathological features and driver gene variants on PD-L1 protein expression in NSCLC patients. Results PD-L1 protein expression was detected in 2 386 cases,with a positive rate of 45.8%(1 093/2 386).Among them,the low expression group(1%≤TPS≤49%)was 62.0%(678/1 093),while the high expression group(TPS≥50%)was 38.0%(415/1 093).There were differences in PD-L1 expression among different clinical and pathological features.Multivariate logistic regression analysis showed that smoking history,lymph node metastasis,pathological subtypes,EGFR mutations,KRAS mutations,ALK and MET mutations were independent risk factors for PD-L1 expression in NSCLC patients(P＜0.05),while lymph node metastasis and EGFR mutations were independent risk factors for PD-L1 expression levels in NSCLC patients(P＜0.05). Conclusion The PD-L1 protein has a high positive rate in patients with smoking,squamous cell carcinoma,KRAS mutant,ALK positive,and MET mutant,and is highly expressed in patients with lymph node metastasis and EGFR wild-type.Different from NSCLC patients with EGFR positive,NSCLC patients with KRAS,and MET positive are expected to benefit from the treatment of immune checkpoint inhibitors.

Key words: Non-small cell lung cancer, Driver gene, Programmed death ligand-1, Immune checkpoint inhibitor

中图分类号:

R734

龙朝恋, 李琨, 刘子臣, 张娜娜, 车南颖. 非小细胞肺癌程序性死亡配体-1表达与临床病理特征和常见驱动基因变异的相关性研究[J]. 实用肿瘤学杂志, 2023, 37(2): 117-122.

LONG Chaolian, LI Kun, LIU Zichen, ZHANG Nana, CHE Nanying. The correlation between the expression of programmed death ligand 1 in non-small cell lung cancer and clinical pathological features and common driver gene mutation[J]. Journal of Practical Oncology, 2023, 37(2): 117-122.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.02.005

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I2/117

参考文献

1 Siegel RL,Miller KD,Fuchs HE,et al.Cancer Statistics,2021[J].CA Cancer J Clin,2021,71(1):7-33.
2 Zheng RS,Zhang SW,Zeng HM,et al.Cancer incidence and mortality in China,2016[J].JNCC,2022,2(1):1-9.
3 Herbst RS,Morgensztern D,Boshoff C.The biology and management of non-small cell lung cancer[J].Nature,2018,553(7689):446-454.
4 Bailey MH,Tokheim C,Porta-Pardo E,et al.Comprehensive characterization of cancer driver genes and mutations[J].Cell,2018,173(2):371-385.
5 Sánchez-Magraner L,Gumuzio J,Miles J,et al.Functional engagement of the PD-1/PD-L1 complex but not PD-L1 expression is highly predictive of patient response to immunotherapy in non-small-cell lung cancer.J Clin Oncol,2023,41(14):2561-2570.
6 Mok TSK,Wu YL,Kudaba I,et al.Pembrolizumab versus chemotherapy for previously untreated,PD-L1-expressing,locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042):a randomised,open-label,controlled,phase 3 trial[J].Lancet,2019,393(10183):1819-1830.
7 Teillaud JL,Dieu-Nosjean MC.Intratumoral plasma cells:More than a predictive marker of response to anti-PD-L1 treatment in lung cancer?[J].Cancer Cell,2022,40(3):240-243.
8 Miyazawa T,Marushima H,Saji H,Kojima K,et al.PD-L1 expression in non-small-cell lung cancer lncluding various adenocarcinoma subtypes[J].Ann Thorac Cardiovasc Surg,2019,25(1):1-9.
9 Gelatti ACZ,Cordeiro de Lima VC,Freitas H,et al.Real-world prevalence of PD-L1 expression among tumor samples from patients with non-small-cell lung cancer.Clin Lung Cancer,2020,21(6):e511-e515.
10 Pawelczyk K,Piotrowska A,Ciesielska U,et al.Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers.Int J Mol Sci,2019,20(4):824.
11 Dantoing E,Piton N,Salaün M,et al.Anti-PD1/PD-L1 immunotherapy for non-small cell lung cancer with actionable oncogenic driver mutations[J].Int J Mol Sci,2021,22(12):6288.
12 Hwang DM,Albaqer T,Santiago RC,et al.Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer[J].J Thorac Oncol,2021,16(9):1490-1500.
13 Peng DH,Rodriguez BL,Diao L,et al.Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers[J].Nat Commun,2021,10,12(1):2606.
14 Akbay EA,Koyama S,Carretero J,et al.Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors[J].Cancer Discov,2013,3(12):1355-1363.
15 Song Z,Yu X,Cheng G,et al.Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma[J].J Transl Med,2016,14(1):188.
16 Lee SE,Kim YJ,Sung M,et al.Association with PD-L1 expression and clinicopathological features in 1000 lung cancers:A large single-institution study of surgically resected lung cancers with a high prevalence of EGFR mutation[J].INT J MOL SCI,2019,20(19):4794.
17 Reck M,Carbone DP,Garassino M,et al.Targeting KRAS in non-small-cell lung cancer:recent progress and new approaches[J].Ann Oncol,2021,32(9):1101-1110.
18 Schoenfeld AJ,Rizvi H,Bandlamudi C,et al.Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas[J].Ann Oncol,2020,31(5):599-608.
19 Pan LN,Ma YF,Li Z,et al.KRAS G12V mutation upregulates PD-L1 expression via TGF-β/EMT signaling pathway in human non-small-cell lung cancer[J].Cell Biol Int,2021,45(4):795-803.
20 Yang CY,Liao WY,Ho CC,et al.Association of programmed death-ligand 1 expression with fusion variants and clinical outcomes in patients with anaplastic lymphoma kinase-positive lung adenocarcinoma receiving crizotinib[J].Oncologist,2020,25(8):702-711.
21 Ota K,Azuma K,Kawahara A,et al.Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer[J].Clin Cancer Res,2015,21(17):4014-4021.
22 Song Z,Yu X,Cheng G,et al.Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma[J].J Transl Med,2016,14(1):188.
23 Elangovan A,Allegretti JR,Fischer M.Microbiota modulation-based therapy for luminal GI disorders:current applications of probiotics and fecal microbiota transplantation.Expert Opin Biol Ther,2019,19(12):1343-1355.
24 王珊.PD-1/PD-L1蛋白表达与非小细胞肺癌K-RAS基因突变的相关性研究[D].唐山:华北理工大学,2017.
25 Kato S,Subbiah V,Marchlik E,et al.RET aberrations in diverse cancers:Next-generation sequencing of 4,871 patients[J].Clin Cancer Res,2017,23(8):1988-1997.
26 Mushtaq R,Cortot AB,Gautschi O,et al.PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer-an IMMUNOTARGET case series[J].Transl Lung Cancer Res,2022,11(12):2412-2417.

[1]	杨磊, 张正凤, 王大榛, 娄长杰. 基于真实世界的晚期食管鳞癌一线标准化疗联合免疫检查点抑制剂对比标准化疗的回顾性对照研究[J]. 实用肿瘤学杂志, 2022, 36(6): 538-543.
[2]	徐子涵, 于国华, 聂玉辉, 孙蒙蒙, 丰慧, 刘淑真. 外周血标志物对晚期非小细胞肺癌免疫相关不良反应的预测作用及与生存结局的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(6): 544-550.
[3]	朱开彬, 贺长军, 陈澜涛, 孔祥龙, 赵苏, 徐世东. TAM通过PLGF/Flt-1和TGF-β1通路促进非小细胞肺癌生长和肿瘤血管异生的研究[J]. 实用肿瘤学杂志, 2022, 36(5): 391-397.
[4]	刘倩倩, 尚利华. 晚期非小细胞肺癌免疫治疗相关不良反应与疗效的相关性研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 463-467.
[5]	董琳, 刘欣, 鲁海玲. 晚期非小细胞肺癌抗血管生成治疗联合免疫检查点抑制剂的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 351-355.
[6]	张浩, 杨新官, 何涌. 肌少症与晚期非小细胞肺癌临床病理特征及预后的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(3): 214-219.
[7]	易小琦, 邓红彬. PD-1/PD-L1抑制剂在膀胱癌新辅助治疗中的应用进展[J]. 实用肿瘤学杂志, 2022, 36(2): 183-187.
[8]	唐菊, 尚利华. BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系[J]. 实用肿瘤学杂志, 2022, 36(2): 188-192.
[9]	张梦茹, 曹德东, 戈伟. 恩度静脉持续泵入与滴注联合含铂双药方案化疗治疗晚期非小细胞肺癌的疗效与安全性比较[J]. 实用肿瘤学杂志, 2022, 36(1): 20-25.
[10]	刘金爽, 张文静, 黎清炜, 李志伟. 免疫检查点抑制剂的联合治疗在胰腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 49-53.
[11]	罗雯, 贾莉, 张佳文, 王冬杰, 孔英君. circRNA MYO1C对肺癌细胞自噬和肿瘤干细胞分化的影响[J]. 实用肿瘤学杂志, 2021, 35(6): 500-505.
[12]	于园园, 孟千皓, 王广雨. 胃癌免疫治疗困境与未来方向[J]. 实用肿瘤学杂志, 2021, 35(6): 552-556.
[13]	刘菲, 隋红. 基于肿瘤免疫微环境的肝癌分子分型研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 557-561.
[14]	李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.
[15]	汪叶, 尚乃舰. 影像组学在非小细胞肺癌诊疗中的应用进展[J]. 实用肿瘤学杂志, 2021, 35(5): 485-488.

非小细胞肺癌程序性死亡配体-1表达与临床病理特征和常见驱动基因变异的相关性研究

The correlation between the expression of programmed death ligand 1 in non-small cell lung cancer and clinical pathological features and common driver gene mutation

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价